{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023520","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.119779+00:00","generated_at":"2026-06-22T00:48:17.650331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LENSAR Q3 2022 revenue down 6% to $7.7M; net loss narrows to $4.0M; launches ALLY system","bullets":["Revenue $7.7M, down 6% YoY; U.S. procedure volume up 9%, offset by South Korean reimbursement challenges.","Net loss of $4.0M (-$0.39 per share) improved from $6.2M loss (-$0.65) in Q3 2021; Adjusted EBITDA -$1.6M.","Launched ALLY Adaptive Cataract Treatment System in the U.S. in August 2022; first installations with positive surgeon feedback.","R&D expenses dropped 50% to $1.6M as ALLY development costs capitalized after June 2022 clearance.","Approximately 88% of revenue from recurring sources; worldwide procedure volume 28,453 in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023520","json":"https://secwatch.observer/filing/0000950170-22-023520.json","markdown":"https://secwatch.observer/filing/0000950170-22-023520.md","text":"https://secwatch.observer/filing/0000950170-22-023520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000095017022023520/0000950170-22-023520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000095017022023520/lnsr-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:48:17.650331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d15c7494df36e980bcb6c5e9a5f0ebb0fa548ea","claim":"LENSAR, Inc. reported the quarter ended September 30, 2022 results: revenue $7.7 million, net income $4.0 million, or ($0.39) per share.","evidence_excerpt":"with 2.5 - 3 minutes when using prior generation and competitive technologies.” Third Quarter 2022 Financial Results Total revenue for the quarter ended September 30, 2022 was $7.7 million, a decrease of $0.5 million, or 6%, compared to total revenue of $8.3 million for the quarter ended September 30, 2021. The decrease in third quarter 2022 revenue was associated","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1320350/000095017022023520/0000950170-22-023520-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$7.7 million"},{"label":"Net income","value":"$4.0 million, or ($0.39) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}